GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » Price-to-Tangible-Book

CLLS (Cellectis) Price-to-Tangible-Book : 1.44 (As of Dec. 13, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cellectis Price-to-Tangible-Book?

As of today (2024-12-13), Cellectis's share price is $1.85. Cellectis's Tangible Book per Share of Sep. 2024 for the quarter that ended in Sep. 2024 was $1.29. Hence, Cellectis's Price to Tangible Book Ratio of today is 1.44.

The historical rank and industry rank for Cellectis's Price-to-Tangible-Book or its related term are showing as below:

CLLS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.76   Med: 2.56   Max: 6.11
Current: 1.54

During the past 13 years, Cellectis's highest Price to Tangible Book Ratio was 6.11. The lowest was 0.76. And the median was 2.56.

CLLS's Price-to-Tangible-Book is ranked better than
72.24% of 1203 companies
in the Biotechnology industry
Industry Median: 2.93 vs CLLS: 1.54

A closely related ratio is called PB Ratio. As of today, Cellectis's share price is $1.85. Cellectis's Book Value per Sharefor the quarter that ended in Sep. 2024 was $1.29. Hence, Cellectis's P/B Ratio of today is 1.43.


Cellectis Price-to-Tangible-Book Historical Data

The historical data trend for Cellectis's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Price-to-Tangible-Book Chart

Cellectis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.32 4.10 1.68 0.82 2.63

Cellectis Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.16 2.63 2.12 1.27 1.65

Competitive Comparison of Cellectis's Price-to-Tangible-Book

For the Biotechnology subindustry, Cellectis's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectis's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Cellectis's Price-to-Tangible-Book falls into.



Cellectis Price-to-Tangible-Book Calculation

Cellectis's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Sep. 2024 )
=1.85/1.286
=1.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Cellectis Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Cellectis's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectis Business Description

Traded in Other Exchanges
Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.